A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
The pandemic provided the best and worst of times for smid-cap medtechs.
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.